*Correspondence: Yongping Liu, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The COMBO-DN study was a large, double-blind, randomized clinical trial that compared the efficacy and safety of high-dose monotherapy versus combination therapy with duloxetine and pregabalin in patients with DPN who had not responded to standard doses [126]
Hasan N, Imran M, Sheikh A, Saad S, Chaudhary G, Jain GK, et al
It's not the right starting point for diagnosed conditions like melasma or significant pigmentation
Sharfuddin AA, Molitoris BA